Monte Rosa Therapeutics (GLUE) Other Operating Expenses (2022 - 2025)
Monte Rosa Therapeutics (GLUE) posted quarterly Other Operating Expenses of $59000.0 for Q1 2025, up 145.83% quarter-over-quarter from $24000.0 in Q2 2023.
Powered by 
Analysis
Monte Rosa Therapeutics (GLUE) Other Operating Expenses (2022 - 2025) Analysis & Trends
Monte Rosa Therapeutics' Other Operating Expenses history runs 3 years deep, the most recent figure standing at $59000.0 for Q1 2025.
- In Q1 2025, Other Operating Expenses changed N/A year-over-year to $59000.0; the TTM figure through Dec 2025 stood at $59000.0 (changed N/A YoY), while the FY2025 annual figure was $59000.0, changed N/A from the prior year.
- Other Operating Expenses for Q1 2025 stood at $59000.0, up from $24000.0 in the prior quarter.
- The five-year high for Other Operating Expenses was $125000.0 in Q1 2022, with the low at -$16000.0 in Q3 2022.
- The 3-year median for Other Operating Expenses is $41500.0 (2023), against an average of $48000.0.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Monte Rosa Therapeutics | 1.42 Bn | 785.27 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 59,000.00 |
| Jun 30, 2023 | 24,000.00 |
| Sep 30, 2022 | -16,000.00 |
| Mar 31, 2022 | 125,000.00 |